⌕
Rhythm Pharmaceuticals · RYTM · Nasdaq
Tenet 36 · Weak
Compare
$116.61+8.49%At closeTenet 36 · Weak
$116.61+9.13 (+8.49%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Rhythm Pharmaceuticals (RYTM) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

The percentage on each card is RYTM's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

● BenzingaNov 17, 2026 · 11:59 ET
Rhythm Pharmaceuticals Shares See Volume; Traders Circulate M&A Rumors At $150/Share

� 2025 Benzinga.com. Benzinga does not provide investment advice.…

RYTM +8.5% todayRead at source ↗
● BenzingaNov 17, 2026 · 10:11 ET
Rhythm Pharmaceuticals Says Rare Obesity Drug Delivers Sustained Two-Year BMI Reductions

Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM) on Monday presented two-year Phase 3 setmelanotide results and global diagnostic criteria at ObesityWeek 2026, highlighting sustained weight reductions and earlier diagnosis for …

RYTM +8.5% todayRead at source ↗
● GlobeNewsWireNov 16, 2026 · 16:00 ETCOMPANY'S OWN WORDS
Rhythm Pharmaceuticals Announces Presentation of New Data at ObesityWeek® 2026

– Two-year results from Phase 3 TRANSCEND trial showed continuous setmelanotide therapy sustained BMI reductions in patients with acquired hypothalamic obesity –…

RYTM +8.5% todayRead at source ↗
● Defense WorldNov 11, 2026 · 03:54 ET
Rhythm Pharmaceuticals (NASDAQ:RYTM) & Senti Biosciences (NASDAQ:SNTI) Head to Head Survey

Senti Biosciences (NASDAQ: SNTI - Get Free Report) and Rhythm Pharmaceuticals (NASDAQ: RYTM - Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two businesses based o…

RYTM +8.5% todayRead at source ↗
● Seeking AlphaNov 10, 2026 · 09:56 ET
Rhythm Pharmaceuticals: Bull Case Intact, But The Market Is Pricing In A Lot

Rhythm Pharmaceuticals maintains strong commercial momentum, with IMCIVREE sales up 79.5% YoY and a broadening prescriber base in the acquired HO. RYTM's valuation is elevated at 27.4x trailing sales, reflecting high exp…

RYTM +8.5% todayRead at source ↗
● WSJNov 4, 2026 · 15:57 ET
AstraZeneca Made $10 Billion Offer for Rhythm Pharmaceuticals

AstraZeneca recently made a roughly $10 billion offer to buy Rhythm Pharmaceuticals, according to people familiar with the matter, a deal that would expand its portfolio of rare disease treatments.…

RYTM +8.5% todayRead at source ↗
● GlobeNewsWireNov 4, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Rhythm Pharmaceuticals Announces NICE Guidance for IMCIVREE® (Setmelanotide) Updated to Include Adults Living with Bardet-Biedl Syndrome

-- Expanded guidance based on additional evidence demonstrating the benefits of IMCIVREE in adults living with Bardet-Biedl syndrome -- BOSTON, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM…

RYTM +8.5% todayRead at source ↗
● Seeking AlphaNov 3, 2026 · 14:55 ET
Rhythm Pharmaceuticals, Inc. (RYTM) Q3 2026 Earnings Call Transcript

Rhythm Pharmaceuticals, Inc. (RYTM) Q3 2026 Earnings Call Transcript…

RYTM +8.5% todayRead at source ↗
● MarketBeatNov 3, 2026 · 14:15 ET
Rhythm Pharmaceuticals Q3 Earnings Call Highlights

Rhythm Pharmaceuticals NASDAQ: RYTM reported third-quarter global net product sales of $92.1 million, up 29% sequentially, as the company cited a strong early U.S. launch for IMCIVREE in acquired hypothalamic obesity, or…

RYTM +8.5% todayRead at source ↗
● Zacks Investment ResearchNov 3, 2026 · 09:16 ET
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q3 Loss, Beats Revenue Estimates

Rhythm Pharmaceuticals, Inc. (RYTM) came out with a quarterly loss of $0.61 per share versus the Zacks Consensus Estimate of a loss of $0.68. This compares to a loss of $0.82 per share a year ago.…

RYTM +8.5% todayRead at source ↗
● GlobeNewsWireNov 3, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Rhythm Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Update

-- Strong U.S. launch momentum for IMCIVREE ® (setmelanotide) for acquired hypothalamic obesity (HO) continues with more than 700 patient start forms as of September 30, 2026 -- -- Third quarter 2026 net product revenue …

RYTM +8.5% todayRead at source ↗
● GlobeNewsWireNov 2, 2026 · 21:59 ETCOMPANY'S OWN WORDS
Rhythm Pharmaceuticals and LG Chem Enter into Amendment to Bivamelagon Exclusive License Agreement

-- Amendment revised royalty structure from low-to-mid-single digits to 1% on global net sales of Rhythm MC4R agonists, including setmelanotide, bivamelagon and RM-718 -- -- Rhythm to pay LG Chem additional fixed payment…

RYTM +8.5% todayRead at source ↗
● Zacks Investment ResearchOct 27, 2026 · 11:06 ET
Rhythm Pharmaceuticals, Inc. (RYTM) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

Rhythm Pharmaceuticals (RYTM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.…

RYTM +8.5% todayRead at source ↗
● Defense WorldOct 25, 2026 · 04:15 ET
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Stock Has Consensus Target Price of $142.50 According to Brokerages

Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM - Get Free Report) have earned an average recommendation of "Moderate Buy" from the twenty-two ratings firms that are covering the stock, MarketBeat.com reports. One r…

RYTM +8.5% todayRead at source ↗
● GlobeNewsWireOct 21, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Rhythm Pharmaceuticals to Report Third Quarter 2026 Financial Results on Tuesday, November 3, 2026

BOSTON, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine dis…

RYTM +8.5% todayRead at source ↗
● GlobeNewsWireOct 13, 2026 · 19:30 ETCOMPANY'S OWN WORDS
Rhythm Pharmaceuticals Announces Commercial Launch of IMCIVREE® (setmelanotide) in Japan for Patients with Acquired Hypothalamic Obesity

-- Launch follows MHLW approval of IMCIVREE for acquired hypothalamic obesity and inclusion on Japan's National Health Insurance drug price list -- -- IMCIVREE is the first approved therapy in Japan for patients living w…

RYTM +8.5% todayRead at source ↗
● Zacks Investment ResearchOct 13, 2026 · 13:00 ET
Rhythm Pharmaceuticals (RYTM) Upgraded to Buy: Here's What You Should Know

Rhythm Pharmaceuticals (RYTM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.…

RYTM +8.5% todayRead at source ↗
● PRNewsWireSep 28, 2026 · 09:10 ET
Kuehn Law Encourages Investors of Rhythm Pharmaceuticals, Inc. to Contact Law Firm

NEW YORK, Sept. 28, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) breached their fiduciary…

RYTM +8.5% todayRead at source ↗
● GlobeNewsWireSep 22, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Rhythm Pharmaceuticals Announces Health Canada Approval of IMCIVREE® (setmelanotide) for Weight Management in Adult and Pediatric Patients 4 years of Age and Older with Acquired Hypothalamic Obesity

BOSTON, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine di…

RYTM +8.5% todayRead at source ↗
● Defense WorldSep 16, 2026 · 04:10 ET
David Meeker Sells 50,000 Shares of Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock

Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM - Get Free Report) CEO David Meeker sold 50,000 shares of the company's stock in a transaction that occurred on Monday, September 14th. The shares were sold at an average price …

RYTM +8.5% todayRead at source ↗
● Defense WorldSep 16, 2026 · 01:21 ET
Rhythm Pharmaceuticals (NASDAQ:RYTM) Trading Down 5.3% on Insider Selling

Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM - Get Free Report) traded down 5.3% during mid-day trading on Tuesday after an insider sold shares in the company. The company traded as low as $97.67 and last traded at $97.035…

RYTM +8.5% todayRead at source ↗
● Seeking AlphaSep 15, 2026 · 15:51 ET
Rhythm Pharmaceuticals, Inc. (RYTM) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Rhythm Pharmaceuticals, Inc. (RYTM) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript…

RYTM +8.5% todayRead at source ↗
● GlobeNewsWireSep 10, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Rhythm Pharmaceuticals Announces New Data Presentations at the European Society for Paediatric Endocrinology Meeting

-- Real-world data showed reductions in BMI with up to 18 months of setmelanotide therapy in 30 paediatric patients with acquired hypothalamic obesity (HO) in France – -- Phase 3 analyses demonstrated improvements across…

RYTM +8.5% todayRead at source ↗
● Defense WorldAug 28, 2026 · 03:59 ET
Bank of New York Mellon Corp Purchases Shares of 394,044 Rhythm Pharmaceuticals, Inc. $RYTM

Bank of New York Mellon Corp acquired a new position in Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acq…

RYTM +8.5% todayRead at source ↗
● GlobeNewsWireAug 24, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Rhythm Pharmaceuticals Announces MHLW Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity (HO) in Japan

-- Approximately 5,000 to 8,000 patients estimated to be living with acquired HO in Japan --  -- Commercial launch in Japan expected by end of 2026, pending final pricing determination --…

RYTM +8.5% todayRead at source ↗

Kept in their own lane. A press release is the company talking, not reporting.

No upcoming events in the feeds.

NVDA33−0.4%
DLB4−3.8%
WDAY4−5.8%

Article counts from the last market-wide feed page, across every symbol we track and not just RYTM · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.